Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Oncology . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN108409649B details a high-yield synthesis route for 5-bromo-7-trifluoromethyl quinoline, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN106243111A details robust synthesis for E1 inhibitors. Offers high purity and scalable routes for pharmaceutical intermediate manufacturing supply chains.
Patent CN114075143A reveals a one-pot synthesis for Olaparib intermediates, eliminating unstable phosphorus ylide isolation to ensure high purity and cost-effective manufacturing.
Patent CN110117254B reveals a streamlined 3-step route for Cabozantinib, replacing hazardous nitration with efficient one-pot reduction and copper-catalyzed decarboxylation for superior supply chain stability.
Patent CN111116593A details a continuous, low-cost Ibrutinib synthesis featuring raw material recycling and simplified purification for scalable pharmaceutical manufacturing.
Patent CN1247573C reveals a high-yield route for CDK inhibitor intermediates, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN113024454A reveals a novel synthesis for brigatinib intermediates, offering cost reduction in API manufacturing and enhanced supply chain reliability.
Novel synthesis of aminopeptidase inhibitors via thiadiazole coupling. Offers cost-effective routes for antitumor drug development and reliable supply.
Patent CN101560206A details a high-yield synthesis route for pemetrexed intermediates, offering significant cost reduction and scalable manufacturing for global supply chains.
Patent CN102584732B reveals a novel crystallization method for Plerixafor synthesis, offering superior purity and cost reduction in API manufacturing for global supply chains.
Novel green route for Abemaciclib intermediate using Selectfluor. Eliminates Palladium residues and reduces costs. Ideal for API manufacturing scale-up.
Novel alkali-modified mesoporous molecular sieve catalyst replaces NaOH for high-yield, scalable Pemetrexed Disodium production with superior purity.
Patent CN108239091B details a robust chemical resolution for NLG919 precursors. This method offers high optical purity, recoverable reagents, and scalable manufacturing for pharmaceutical supply chains.
Novel low-cost route for EGFR inhibitor intermediates via early acylation strategy ensuring high purity and supply stability for global pharmaceutical partners.
Novel synthesis route for gamma-butyrolactone dimer anticancer compounds offers high purity and scalable manufacturing for pharmaceutical intermediates supply chains.
Explore advanced synthesis of 2-(6-aminobenzothiazole-2-mercapto)-acetamide derivatives. Reliable pharmaceutical intermediate supplier offering cost-effective Tie2 inhibitor routes.
Patent CN111471020B reveals a novel Rh-catalyzed route for Avapritinib intermediates, offering safer conditions and reduced costs for reliable API manufacturing.
Advanced refining method for Lenvatinib Mesylate achieving >99.8% purity. Optimized crystallization reduces costs and ensures supply chain reliability for pharmaceutical manufacturers.
Novel indazole-triazole derivatives with specific anti-prostate cancer activity. Efficient synthesis route offers cost reduction and scalable supply for pharmaceutical intermediates.
Patent CN106795198B enables high yield synthesis. Reduces costs and improves supply chain reliability for oncology intermediate manufacturing globally.